Pfizer Inc (PFE)
Working capital turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 58,496,000 | 100,330,000 | 81,288,000 | 41,651,000 | 50,108,000 |
| Total current assets | US$ in thousands | 43,333,000 | 51,259,000 | 59,693,000 | 35,067,000 | 32,803,000 |
| Total current liabilities | US$ in thousands | 47,794,000 | 42,138,000 | 42,671,000 | 25,920,000 | 37,304,000 |
| Working capital turnover | — | 11.00 | 4.78 | 4.55 | — |
December 31, 2023 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $58,496,000K ÷ ($43,333,000K – $47,794,000K)
= —
The working capital turnover of Pfizer Inc. has shown a fluctuating trend over the past five years. In 2020, the working capital turnover was 4.58, indicating that Pfizer generated $4.58 in revenue for every dollar of working capital invested in that year. This ratio increased to 4.78 in 2021, suggesting a slightly more efficient use of working capital compared to the previous year.
Notably, in 2022, Pfizer significantly improved its working capital turnover to 11.00, indicating a substantial increase in efficiency in utilizing its working capital to generate revenue. However, the working capital turnover for 2023 is not provided in the table for a direct comparison.
Overall, an increasing trend in the working capital turnover ratio signifies that Pfizer is becoming more efficient in utilizing its working capital to generate sales revenue, which is a positive indicator of the company's operational effectiveness.
Peer comparison
Dec 31, 2023